PET Study With [89Zr]-Df-CriPec® Docetaxel
NCT03712423 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7
Last updated 2020-10-08
Summary
A clinical phase I, open-label PET study with \[89Zr\]-Df-CriPec® docetaxel in patients with solid tumours to assess biodistribution and tumour accumulation of \[89Zr\]-Df-CriPec® docetaxel.
Conditions
Interventions
- DRUG
-
Cripec Docetaxel
89 Zirconium Cripec Docetaxel PET
Sponsors & Collaborators
-
Cristal Therapeutics
collaborator INDUSTRY -
Amsterdam UMC, location VUmc
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-04-01
- Primary Completion
- 2020-03-25
- Completion
- 2020-05-08
Countries
- Netherlands
Study Locations
More Related Trials
-
Non-invasive Imaging of Cetuximab-Zr. 89 Uptake Wit PET: a Phase I Trial in Stage IV Cancer Patients
NCT00691548 ·Status: COMPLETED ·Phase: PHASE1
-
MPDL3280A-imaging-IST-UMCG
NCT02453984 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
89Zr-labeled NY009 PET Imaging in Patients
NCT05691855 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
DK222 Study at Hopkins
NCT07140315 ·Status: RECRUITING ·Phase: PHASE1
-
PET [89Zr]DFO-starPEG in Solid Tumors
NCT06894745 ·Status: RECRUITING ·Phase: PHASE1
-
MPDL3280A-treatment-IST-UMCG
NCT02478099 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study
NCT05955833 ·Status: UNKNOWN ·Phase: PHASE1
-
PET Scans and CT Scans in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy
NCT00388024 ·Status: COMPLETED
-
PET CT With HX4 in Cervix Cancer
NCT02233387 ·Status: TERMINATED ·Phase: PHASE2
-
Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)
NCT03773133 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Serial PET MPI in Patients Undergoing Cancer Treatment
NCT05913999 ·Status: ENROLLING_BY_INVITATION
-
Early Response Evaluation of Proton Therapy by PET-imaging in Squamous Cell Carcinoma Located in the Head and Neck
NCT03513042 ·Status: TERMINATED
-
PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9
NCT05212103 ·Status: ENROLLING_BY_INVITATION
-
Study of the Fixation of Various Vectors in PET/CT in Patients With a With Lung Cancer Before and During of CRT or RT
NCT01261585 ·Status: COMPLETED
-
Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer
NCT01543659 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study Using Whole-body PET After Oral Microdose of 18F-labeled Liporaxel in Patients With Solid Tumor
NCT04046016 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
PET Acetate for Castrate-Resistant Prostate Cancer on Chemotherapy
NCT01144897 ·Status: COMPLETED ·Phase: PHASE1
-
PET/CT Imaging of Angiogenesis in Lung or Head and Neck Cancers Prior or During Chemotherapy With Antiangiogenic Agents
NCT02325349 ·Status: TERMINATED ·Phase: PHASE2
-
PET-CT Based Radiotherapy in Esophageal Cancer Patients
NCT01156831 ·Status: COMPLETED
-
Biodistribution and Dosimetry of 99mTc-Duramycin
NCT05177640 ·Status: COMPLETED ·Phase: PHASE1
-
Specimen PET-CT Imaging for Intraoperative Margin Assessment in Breast Cancer
NCT04999917 ·Status: COMPLETED ·Phase: NA
-
PET-DECT for Staging and Imaged Based Radiotherapy Planning in Lung Cancer
NCT03146117 ·Status: TERMINATED
-
PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors
NCT07023848 ·Status: ENROLLING_BY_INVITATION ·Phase: EARLY_PHASE1
-
89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma
NCT01859234 ·Status: UNKNOWN ·Phase: NA
-
PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study
NCT01269593 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1